Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
Benzinga's Top Downgrades
Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest (Investor's Business Daily)
Related XNPT
Benzinga's M&A Chatter for Monday May 23, 2016
Mid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Sep 2016JefferiesDowngradesBuyHold
Aug 2016Morgan StanleyMaintainsOverweight
Aug 2016Standpoint ResearchDowngradesBuyHold

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!